Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX + Bevacizumab in Rectal Cancer
NCT01426074Phase 2Withdrawn
- Sponsor
- Abramson Cancer Center
- Start
- Aug 2011
- Primary completion
- Jun 2014
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in rectal cancer (2 arms), sponsored by Abramson Cancer Center. Primary endpoints: Pathologic Complete Response, Time to Progression and 4 more. Planned start Aug 2011; status: withdrawn.
02
Drugs
bevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01426074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01426074.